59215-41-7

Basic information

• Product Name: 4-piperazin-1-ylquinazoline
• Synonyms: 4-piperazin-1-ylquinazoline;4-piperazin-1-ylquinazoline(SALTDATA: 2HCl 1.7H2O);4-piperazin-1-ylquinazoline 2HCl 1.7H2O;4-(1-piperazinyl)quinazoline;4-piperazin-1-ylquinazoline hydrochloride;4-Piperazin-1-yl-quinazoline 2HCl
• CAS NO: 59215-41-7
• Molecular Formula: C₁₂H₁₄N₄
• Molecular Weight: 214.26636
• Mol File: 59215-41-7.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 411°C at 760 mmHg
• Flash Point: 202.4°C
• Appearance: /
• Density: 1.201g/cm³
• Vapor Pressure: 5.78E-07mmHg at 25°C
• Refractive Index: 1.634
• Storage Temp.: 2-8°C(protect from light)
• PKA: 8.60±0.10(Predicted)
• CAS DataBase Reference: 4-piperazin-1-ylquinazoline(CAS DataBase Reference)
• NIST Chemistry Reference: 4-piperazin-1-ylquinazoline(59215-41-7)
• EPA Substance Registry System: 4-piperazin-1-ylquinazoline(59215-41-7)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 59215-41-7(Hazardous Substances Data)

Usage

General Description

4-piperazin-1-ylquinazoline is a chemical compound that belongs to the class of quinazoline derivatives. It is a heterocyclic organic compound that contains both a piperazine and a quinazoline ring structure. The compound has potential pharmaceutical applications due to its ability to interact with biological systems and its diverse range of properties. 4-piperazin-1-ylquinazoline has been studied for its potential as a therapeutic agent for conditions such as cancer, cardiovascular diseases, and central nervous system disorders. Its unique structure and potential biological activities make it an interesting target for further research and development in the field of medicinal chemistry.

InChI:InChI=1/C12H14N4/c1-2-4-11-10(3-1)12(15-9-14-11)16-7-5-13-6-8-16/h1-4,9,13H,5-8H2

Upstream product

• 110-85-0 piperazine 
• 5190-68-1 4-chloroquinazoline 
• 491-36-1 4-quinazolinol 
• 209733-20-0 4-piperazinylquinazoline hydrochloride 
• 827598-29-8 4-(quinazolin-4-yl)piperazine-1-carboxylic acid tert-butyl ester 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 

Downstream Products

• 1059629-08-1 [4-benzyloxy-5-methoxy-2-nitro-phenyl](4-(4-quinazolinyl)piperazino)-methanone 
• 1186588-61-3 C₃₂H₄₂N₆O₅S₂ 
• 1065540-41-1 N₁-[4-chloro-2-(2-chlorobenzoyl)phenyl]-2-[4-(4-quinazolinyl)piperazino]acetamide 
• 853678-27-0 (2R)-2-amino-3-phenyl-1-(4-quinazolin-4-yl-piperazin-1-yl)-propan-1-one 

Relevant articles and documents

MODULATORS OF RAS GTPASE

RAS modulating compounds and methods of using the same are provided. The compounds find use in modulating the activity of a target RAS in a sample. The target RAS can be a mutant RAS that is implicated in a disease of interest. In some cases, the subject

Molecular docking and synthesis of novel quinazoline analogues as inhibitors of transcription factors NF-κB activation and their anti-cancer activities

NF-kB is a transcription factor protein complex that can be found in almost all animal cell types and is a key player in some cancers and inflammatory responses. It can enhance the proliferation rate, reduce apoptosis, as well as creating more blood flow to ensure the survival of cancer, thus blocking the NF-kB pathway has potential therapeutic benefit. We designed a series of compounds based on a quinazoline scaffold pharmacophore model which may have high binding affinity with the p50 subunit of NF-kB. The compound series with phenyl substitution at the 2 position of the quinazoline proved to be more effective at inhibiting NF-kB function both theoretically and experimentally. These compounds also reduce the proliferation of numerous tumor cell lines and the mean GI50 for compound 2a is 2.88 μM against the NCI-60 cell line. At the same time, compound 2a can induce significant apoptosis in EKVX cell line at the concentration of 1 μM.

PROLINE DERIVATIVES AND USE THEREOF AS DRUGS

The present invention aims at providing compounds having therapeutic effects due to a DPP-IV inhibitory action, and satisfactory as pharmaceutical products. The present inventors have found that derivatives having a substituent introduced into the γ-position of proline represented by the formula (I) wherein each symbol is as defined in the specification, have a potent DPP-IV inhibitory activity, and completed the present invention by increasing the stability.